Ighani Arvin, Yu Ashley M, Sandhu Vijay K, Barankin Benjamin, Manolson Morris F
1 Faculty of Medicine, University of Toronto, ON, Canada.
2 School of Medicine, University of Ottawa, ON, Canada.
J Cutan Med Surg. 2019 Mar/Apr;23(2):148-156. doi: 10.1177/1203475418808764. Epub 2019 Feb 25.
: There is ongoing development of new therapies for psoriasis, including biologic and systemic agents such as interleukin-17, interleukin-23, and phosphodiesterase-4 inhibitors. The development of these agents has changed the landscape of psoriasis treatment options.
: The objective of this study was to characterize the impact of newer biologic and systemic agents approved by June 2016 on patient outcomes. We sought to evaluate and compare biologic users and nonbiologic systemic users with respect to their treatment awareness and satisfaction.
: We conducted a national Canadian survey from July to September 2016 on adult patients with moderate-to-severe psoriasis using biologic agents or nonbiologic systemic agents as their current primary treatment modality. Patients were asked to evaluate their overall satisfaction with their treatment agent and their awareness of other treatment options. Responses from biologic and nonbiologic systemic users were compared.
: Overall, 343 participants were included (biologic users: n = 218; nonbiologic users: n = 125). Treatment satisfaction: Biologic users had a higher overall satisfaction score than nonbiologic users ( P < .001). Among nonbiologic agents, apremilast (62%) was associated with the highest satisfaction proportion. Among biologic agents, ustekinumab (77%) and adalimumab (72%) were associated with the highest proportions of satisfaction. With respect to treatment awareness, 30% of nonbiologic patients did not have enough information to form an opinion about biologics.
: This study demonstrates the greater treatment satisfaction of biologic users compared with nonbiologic users for moderate-to-severe psoriasis. Given that nearly one-third of nonbiologic users did not have enough information to form an opinion about biologic agents, physicians may consider counselling these patients on the use of biologic agents for psoriasis management.
针对银屑病的新疗法不断涌现，包括生物制剂和全身性药物，如白细胞介素 - 17、白细胞介素 - 23和磷酸二酯酶 - 4抑制剂。这些药物的研发改变了银屑病的治疗选择格局。
本研究的目的是描述2016年6月前获批的新型生物制剂和全身性药物对患者治疗结果的影响。我们试图评估并比较生物制剂使用者和非生物制剂全身性药物使用者在治疗认知和满意度方面的情况。
2016年7月至9月，我们在加拿大全国范围内对成年中重度银屑病患者进行了一项调查，这些患者目前主要使用生物制剂或非生物制剂全身性药物进行治疗。患者被要求评估他们对治疗药物的总体满意度以及对其他治疗选择的认知。对生物制剂使用者和非生物制剂全身性药物使用者的回答进行了比较。
总共纳入了343名参与者（生物制剂使用者：n = 218；非生物制剂使用者：n = 125）。治疗满意度：生物制剂使用者的总体满意度得分高于非生物制剂使用者（P <.001）。在非生物制剂中，阿普斯特（62%）的满意度比例最高。在生物制剂中，乌司奴单抗（77%）和阿达木单抗（72%）的满意度比例最高。在治疗认知方面，30%的非生物制剂患者没有足够信息对生物制剂形成看法。
本研究表明，与非生物制剂使用者相比，生物制剂使用者对中重度银屑病的治疗满意度更高。鉴于近三分之一的非生物制剂使用者没有足够信息对生物制剂形成看法，医生可能会考虑就使用生物制剂治疗银屑病向这些患者提供咨询。
